Abstracts tagged "pregnancy"

Abstract Number: 1824 • ACR Convergence 2023
Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases
Anna Sutton¹, Carolyn Hilliard², Qiuyuan Qin³, Alfred Jared Anzalone⁴, Mary Toth⁵, Rena Patel⁶ and Namrata Singh⁷, ¹Department of Epidemiology, University of Washington School of Public Health, Woodinville, WA, ²Department of Internal Medicine SSM Saint Louis University, St. Louis, MO, ³Department of Public Health, University of Rochester, Rochester, NY, ⁴Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, ⁵Nemours Foundation, Orlando, FL, ⁶Departments of Medicine and Global Health, University of Washington, Seattle, WA, ⁷University of Washington, Bellevue, WA
Background/Purpose: Acknowledgment: Contributed on behalf of the National COVID Cohort Collaborative (N3C) ConsortiumIndividuals with rheumatologic diseases (RD) are at higher risk for severe COVID-19 compared…
Abstract Number: 0473 • ACR Convergence 2023
The Number of Rheumatoid Arthritis Patients Who Give up Pregnancy Due to the Disease Is Decreasing
Ryo Inoue¹, Sakiko Isojima¹, Toshihiro Matsui², Shigeto Tohma³ and Nobuyuki Yajima⁴, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa City, Tokyo, Japan, ²NHO Sagamihara National Hospital, Kanagawa, Japan, ³NHO Tokyo National Hospital, Dallas, TX, ⁴Showa-Universtiy of Medicine, Tokyo, Japan
Background/Purpose: Biologics have been shown not to be a disruption in pregnancy, and the reproductive health care environment surrounding rheumatoid arthritis patients has improved significantly.…
Abstract Number: 1349 • ACR Convergence 2023
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…
Abstract Number: 1968 • ACR Convergence 2023
Pregnancy Outcomes in Idiopathic Inflammatory Myopathies: A Comparison to the General American Population
Ana Valle¹, Melissa Fazzari² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare autoimmune conditions which cause multi-organ inflammation, particularly in the skin, lungs, and muscles. It is known that many…
Abstract Number: 0474 • ACR Convergence 2023
Acute Cardiovascular Events During Pregnancy and Delivery in Patients with Autoimmune Rheumatic Diseases (ARDs): An Analysis of National Inpatient Sample
Karun Shrestha¹, Prakriti Subedi¹, Manoj Ghimire¹, Sajana Poudel², Kalpana Ghimire¹, Sai Keerthi Parvatheneni¹, Mrunalini Dandamudi¹, Laura Pedraza¹, Luisa Brito¹ and Liliya Gandrabur³, ¹Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY, ²Department of Internal Medicine, John H Stroger Jr Hospital of Cook County, Chicago, IL, ³SBH Health System, Forest Hills, NY
Background/Purpose: Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) & vasculitis are autoimmune rheumatic diseases (ARDs) with systemic involvement. Management of women with ARDs during pregnancy…
Abstract Number: 1350 • ACR Convergence 2023
Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record
Noah Forrest¹, Joshua Waytz², April Barnado³, Megan Clowse⁴, Theresa Walunas¹ and Rosalind Ramsey-Goldman⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern Medicine, Chicago, IL, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Duke University, Chapel Hill, NC, ⁵Northwestern University, Chicago, IL
Background/Purpose: SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in…
Abstract Number: 2278 • ACR Convergence 2023
Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
Cristiana Sieiro Santos¹, Paula Pérez García², Jose Ordas Martínez², Clara Moriano², Carolina Álvarez Castro² and Elvira Díez Álvarez², ¹Complejo Asistencial Universitario de León, León, Spain, ²CAULE, León, Spain
Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…
Abstract Number: 0475 • ACR Convergence 2023
Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States
Sabahat Usmani¹, Catherine Lavallee², Maria Antonelli³ and Cuoghi Edens⁴, ¹Weiss Memorial Hospital, Chicago, IL, ²Virginia Tech Carilion School of Medicine, Roanoke, VA, ³MetroHealth System, Cleveland, OH, ⁴University of Chicago, Chicago, IL
Background/Purpose: Endometriosis (ENDO) and Polycystic Ovarian Syndrome (PCOS) are underdiagnosed, often debilitating conditions with unknown etiologies that, like rheumatic diseases, affect reproductive-aged women. Recent studies…
Abstract Number: 1352 • ACR Convergence 2023
Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study
Yanint Raksadawan¹, Aravind Polam¹, Nattanicha Chaisrimaneepan² and Sabahat Usmani¹, ¹Weiss Memorial Hospital, Chicago, IL, ²Texas Tech University Health Sciences, Lubbock, TX
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis which affects women of reproductive age. There is limited information about the effect of TA on…
Abstract Number: 2292 • ACR Convergence 2023
Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus?
Dina Zucchi¹, Giancarlo Cascarano², Antonio Collesei³, Elena Elefante², Francesca Monacci⁴, Chiara Ietto⁴, Linda Carli², Sabrina Gori², Valentina Gelsi⁴, Chiara Tani² and Marta Mosca², ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; Department of Medical Biotechnologies, University of Siena, Pisa, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ³Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Familial Cancer Clinics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy, ⁴Department of Clinical and Experimental Medicine, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients are at risk of disease flare during pregnancy; risk stratification is crucial for personalized treatment and monitoring. Our hypothesis…
Abstract Number: 0476 • ACR Convergence 2023
Factors Associated with the Need for Assisted Reproductive Therapies in a Spanish Cohort of Patients with Rheumatic Diseases
Antía García-Fernández¹, Fernando Rengifo-García¹, Raquel Senosiain-Echarte¹, Miguel álvaro-Navidad¹, Miguel A Gonzalez-Gay² and Juan A Martínez-López¹, ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ²IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Patients with rheumatic diseases (RMD) have a lower pregnancy rate, with infertility being one of the main causes. The rate of assisted reproductive therapies…
Abstract Number: 1354 • ACR Convergence 2023
The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus
Ceshae Harding¹, Amanda Eudy², Catherine Sims¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: Mental health conditions are the leading cause of maternal mortality across most of the United States. Among individuals with SLE, pregnancy intention has been…
Abstract Number: 2305 • ACR Convergence 2023
Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus
Dr Hiba Khogali¹, Ghada Al‐Bluwi², Virgie Guy² and Ali Al Dhanhani³, ¹Tawam Hospital, Al Ain, United Arab Emirates, ²College of Medicine, UAE University, Al Ain, United Arab Emirates, ³UAE University, Al Ain, United Arab Emirates
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnant women with SLE have higher rates of…
Abstract Number: 0477 • ACR Convergence 2023
Continuing TNFi After Pregnancy Diagnosis in Women with Chronic Rheumatic Inflammatory Diseases Is Not Associated with Worse Obstetrical or Infant Outcomes and Seems to Reduce Risk of Maternal Severe Infection: The Results of the Emulated Target Trial BioGRIC
Anna Molto¹, aya ajrouche², Diep Tran², Nathalie Costedoat-Chalumeau³, Elisabeth Elefant⁴, Vassilis Tsatsaris⁵, Jeanne Fresson⁶, Brigitte Bader-Meunier⁵, Bruno Fautrel⁷ and Florence Tubach², ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²Centre de pharmaco-épidémiologie de l'APHP, Paris, France, ³Inserm DR Paris 5, Paris, France, ⁴APHP, Paris, France, ⁵Paris-Cité University, Paris, France, ⁶CHU Nancy, Nancy, France, ⁷Sorbonne Université APHP, Paris, France
Background/Purpose: Many women with chronic rheumatic inflammatory diseases (CRID) stop tumor necrosis factor inhibitors (TNFi) treatment once pregnancy is confirmed to avoid potential adverse fetal…
Abstract Number: 1355 • ACR Convergence 2023
Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices
Rebecca O'Farrell¹, Sinead Maguire², Louise Moore³, Kieran Murray⁴, Áine Gorman⁵, Elisabeth Ball⁶, Claire Riddell⁶, Madeline O'Neill⁷, Natasha Jordan⁸, Barry O'Shea⁹, Douglas Veale¹⁰, Suzanne Donnelly¹¹, Grainne Murphy¹² and Gillian Fitzgerald¹³, ¹Department of Rheumatology, Galway, Dublin, Ireland, ²Toronto Western Hospital, Toronto, ON, Canada, ³Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Harold's Cross,, Ireland, ⁴University Hospital Limerick, Limerick, Ireland, ⁵Royal United Hospital, Bath, United Kingdom, ⁶Belfast Health and Social Care Trust, Belfast, United Kingdom, ⁷Our Lady's Hospice, Harold's Cross, Dublin, Ireland, ⁸Addenbrooke's Hospital, Cambridge, United Kingdom, ⁹St James's Hospital, Dublin, Ireland, ¹⁰St.Vincent's University Hosp, Dublin, Ireland, ¹¹Mater Misericordiae University Hospital, Dublin, Ireland, ¹²Cork University Hospital, Cork, Ireland, ¹³University Hospital Galway, Galway, Ireland
Background/Purpose: Rheumatic disease frequently affects women of childbearing age. Women with pre-existing rheumatic disease who are planning a pregnancy or develop these conditions during pregnancy…

« Previous Page
1
…
4
5
6
7
8
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.